Plumb Pharmaceuticals utilizes its proprietary AQL™ (Advanced Quantload) technology to enhance drug delivery through a sophisticated liposome formation method. This innovative approach involves a three-step process where a loading base is first captured and then efficiently removed, followed by the loading of the drug into the liposome through a "swapping" mechanism. This method not only ensures a high concentration of the drug within the liposome but also facilitates a controlled and prolonged release of the drug after subcutaneous injection, which is particularly beneficial for therapeutic applications.

The AQL™ technology is designed to optimize both loading efficiency and release duration, addressing critical challenges in the pharmaceutical industry, especially in the context of pain and addiction therapies. By enabling a slow and sustained release of the encapsulated drug, Plumb Pharmaceuticals aims to improve treatment outcomes and patient compliance, particularly in areas where traditional drug delivery methods have fallen short. This focus on innovative drug delivery systems positions the company as a forward-thinking player in the pharmaceutical landscape, particularly in the development of new therapies for complex conditions.

United States

Plumb Pharmaceuticals Inc. is a company dedicated to solving problems of medication compliance with extended-release formulations of FDA-approved drugs. Plumb Pharmaceuticals has developed a drug delivery platform for super-extended-release medications based on proprietary liposome preparation and loading. The company's lipid nanoparticle technology offers stimulants for treating ADHD, anti-HIV drugs, antibiotics, antipsychotics, and cancer chemotherapy agents.

Various

1202 Ann Street, Suite 122, Madison, WI 53713-2410, United States

Plumb Pharmaceuticals

Company Details